RxDoctor Payments DataLook up a doctor →

Cedric Willis, PA

Physician Assistant · Shreveport, LANPI 1801196589

Payments from drug & device makers

$12,355in general payments, 2019–2025

Across 738 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Johnson & Johnson$947
  • Takeda Pharmaceuticals U.S.A., Inc.$567
  • QOL Medical, LLC$524
  • Sanofi$514
  • plus $4K from 24 others

What the payments were for

  • Food & beverage$12,18299%
  • Education$1741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,355 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$86,938
Medicare patients
518
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase20$51,292
LinzessLinaclotide43$28,074
IbsrelaTenapanor Hcl11$22,233
TrulancePlecanatide21$15,040
SymproicNaldemedine Tosylate19$8,878
Dexlansoprazole DrDexlansoprazole14$3,929
Colestipol Hcl62$3,080
Omeprazole266$2,549
Sucralfate42$1,819
Esomeprazole Magnesium57$1,311
Pantoprazole Sodium140$1,208
Famotidine166$985
Baclofen34$382
Dicyclomine Hcl20$239
Ondansetron Hcl12$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$258$51,29220 claims
AbbVieLinzess$2,865$28,07443 claims
Ardelyx, Inc.Ibsrela$331$22,23311 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$2,765$15,04021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →